Highlights Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
5.86 ^USD	-3.14%		+10.78%	-9.71%

May. 08	Terns Pharmaceuticals, Inc. Announces Executive Changes	CI
Apr. 29	Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation	Apr. 29	CI
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer	Apr. 10	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity	Nov. 02	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH	23-08-08	CI
Terns Pharmaceuticals, Inc. Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADAâ€™s 83rd Annual Scientific Session	23-06-26	CI
Terns Pharmaceuticals Q1 Net Loss per Share Narrows	23-05-15	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
TERNS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-27	AQ
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-27	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-27	CI
Terns Pharmaceuticals Provides Program Updates	23-03-02	CI
TERNS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-09	AQ
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Terns Pharmaceuticals, Inc. Highlights Results from Phase 1 Clinical Trial of Tern-501 At AASLD The Liver Meeting® 2022	22-11-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Highlights

Filters